60 Degrees Pharmaceuticals (SXTP) & Its Competitors Financial Review

60 Degrees Pharmaceuticals (NASDAQ:SXTP) is one of 894 public companies in the “Pharmaceuticals” industry, but how does it compare to its peers? We will compare 60 Degrees Pharmaceuticals to similar companies based on the strength of its earnings, profitability, analyst recommendations, dividends, institutional ownership, risk and valuation.

Profitability

This table compares 60 Degrees Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
60 Degrees Pharmaceuticals	-650.21%	N/A	-136.81%
60 Degrees Pharmaceuticals Competitors	-2,393.19%	-220.45%	-16.12%

Institutional and Insider Ownership

8.0% of 60 Degrees Pharmaceuticals shares are owned by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 1.7% of 60 Degrees Pharmaceuticals shares are owned by insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and price targets for 60 Degrees Pharmaceuticals and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
60 Degrees Pharmaceuticals	1	2	1	0	2.00
60 Degrees Pharmaceuticals Competitors	7820	13783	25790	1036	2.41

60 Degrees Pharmaceuticals presently has a consensus price target of $13.85, indicating a potential upside of 2,569.11%. As a group, “Pharmaceuticals” companies have a potential upside of 24.87%. Given 60 Degrees Pharmaceuticals’ higher possible upside, analysts clearly believe 60 Degrees Pharmaceuticals is more favorable than its peers.

Risk and Volatility

60 Degrees Pharmaceuticals has a beta of 2.47, meaning that its share price is 147% more volatile than the S&P 500. Comparatively, 60 Degrees Pharmaceuticals’ peers have a beta of -0.05, meaning that their average share price is 105% less volatile than the S&P 500.

Valuation & Earnings

This table compares 60 Degrees Pharmaceuticals and its peers top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
60 Degrees Pharmaceuticals	$1.41 million	-$7.36 million	-0.11
60 Degrees Pharmaceuticals Competitors	$3.54 billion	$3.17 billion	553.74

60 Degrees Pharmaceuticals’ peers have higher revenue and earnings than 60 Degrees Pharmaceuticals. 60 Degrees Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Summary

60 Degrees Pharmaceuticals peers beat 60 Degrees Pharmaceuticals on 8 of the 12 factors compared.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing medicines for tropical and infectious diseases. The company’s work centers on treatments and preventive therapies for conditions that affect travelers, military personnel and populations in regions where infectious diseases are prevalent. Its lead product is Arakoda (tafenoquine), an oral prescription medicine approved by the U.S. Food and Drug Administration in 2018 for the prevention of malaria in adults.